[Effect of Daming capsule on expression of connexin43 isoforms in hyperlipemic rat's cardiac muscle].
OBJECTIVE
To find the molecular mechanism of decreasing blood fat effect of Darning capsule on hyperlipemic rat, we study the expression of connexin43 in the myocardium before and after using the capsule.


METHODS
Forty Wistar rats were randomly divided into 5 group: control group, hyperlipemia model group, Daming capsule group of high dose, middle dose and low dose (200, 100, 50 mg kg(-1) d(-1)). Each group had 8 rats. Hyperlipemic rat model was made firstly, the blood was obtained via vena caudalis and the indexes of TC, TG, LDL, HDL and NEFA in the serum were measured. The myocardial total RNA was extracted by Trizol method. To compare the expression of connexin43 in the following groups: hyperlipemia, normal and drug, we used the technique of RT-PCR, immunostaining and microconfoul.


RESULTS
The concentrations of TC, TG, LDL and NEFA in hyperlipemic serum were increased (P <0. 05), while that of HDL was decreased (P <0. 05). After treating with Daming capsule, the concentration of the preceding four indexes were decreased and the concentrations of HDL was increased up to nearly normal level. No significant difference was found in the ECG of the three groups. As compared with the normal group, the mRNA expressions of connexin43 in hyperlipemia group was weakened (P <0.05), while that of the drug group was enhanced(P <0.05). The same result in immunostaining was observed.


CONCLUSIONS
Hyperlipemic rat model was successfully established and Daming capsule has the effect of lowering blood lipid. Furthermore, the molecular mechanism of Darning capsule is related with the change of Cx43 closely.
Xing
Yan
Y
Department of Pharmacology, Bio-pharmaceutical Key Laboratory of Heilongjiang Province-Incubator of State Key Laboratory, Harbin Medical University, Harbin 150086, China.
Yue
Peng
P
Sun
Li-hua
LH
Zhao
Wen-xiao
WX
Wang
Ying
Y
Zhang
Yong
Y
Liu
Xin
X
Lu
Yan-jie
YJ
Yang
Bao-feng
BF
D000818:Animals; D002214:Capsules; D002784:Cholesterol / Q000097:blood; D018031:Connexin 43 / Q000096:biosynthesis* / Q000235:genetics; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006949:Hyperlipidemias / Q000097:blood / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010946:Plants, Medicinal / Q000737:chemistry; D020033:Protein Isoforms / Q000096:biosynthesis / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
D002214:Capsules; D018031:Connexin 43; D004365:Drugs, Chinese Herbal; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D020033:Protein Isoforms; D012333:RNA, Messenger; D014280:Triglycerides; D002784:Cholesterol